Intrathecal targeted drug delivery systems historically required physician office visits for dose adjustment to manage fluctuating pain. A wireless device now enables patients to supplement their basal intrathecal infusion with a programmed on-demand bolus dose. We sought to quantify the change in oral breakthrough opioid need associated with the use of an intrathecal bolus in comparison to those treated with the basal infusion alone.Demographic, dosage, bolus usage and longevity data were extracted from the historical medical record of 69 patients (18/51 bolus/nonbolus) followed continuously at our center. Medication consumption and Pain Disability Index measures were obtained at baseline and most recent follow-up.Among patients with the bolus option, only 2 (11

作者：Robert B, Bolash；Tariq, Niazi；Meera, Kumari；Gerges, Azer；Nagy, Mekhail

来源：Pain practice : the official journal of World Institute of Pain 2017 年